# Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma

> **NCT01233895** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 26 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** AVE1642
- **DRUG:** Velcade

## Key facts

- **NCT ID:** NCT01233895
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2010-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01233895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01233895, "Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01233895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*